Transforming Cardiac
Surgery Through Innovation

Two award-winning, patented technologies that save lives and reduce complications

With more products in the pipeline, including AI integration.

PerDeCT

Detecting and preventing tamponade during cardiac surgery with a proven monitoring solution.

STHpol Cardioplegia

Protecting patients from heart attacks by temporarily stopping the heart with the right drugs.
2000000

2M Cardiac surgery patients worldwide

Delivering state of the art solutions from the heart of clinical practice in pursuit of optimal cardiothoracic surgery outcomes.

A complex problem with a simple solution: PerDeCT™

Although cardiac surgery is largely safe, some patients develop a life-threatening condition called cardiac tamponade in the immediate postoperative period.

Cardiac tamponade is caused by the collection of blood clots in the pericardial space compressing the heart and compromising the cardiac output.

The diagnosis of tamponade is subjective, difficult, typically happens late at night and can be confused with other causes of heart failure.

The PerDeCT™ device can save lives, improve patient outcomes, reduce overall costs, and has an attractive health economic case for medical device manufacturers.

Patient and User Feedback

  • Key Opinion Leader
    Older, sicker patients demand better myocardial protection. The results (of polarized cardioplegia) are promising and underline the potential of polarised arrest.

    Key Opinion Leader

  • End User - Expression of Interest
    If this is shown to be a reliable cardiac monitoring device that could be placed on the PA after surgery and easily removed, I would use it in every patient.

    End User - Expression of Interest

  • Patient's Spouse
    XXX had straightforward mitral valve operation and developed tamponade. I was next to her when her heart stopped, they ushered me out and drew the curtains to open her up on the intensive care unit. This will remain the most traumatic experience in my life. I thought I lost her. Now I know XXX was lucky to have survived. This device should be available to every patient because this should not happen to anyone.

    Patient's Spouse

  • Perfusion Lead, Major Hospital
    Cardioplegia has been plagued with supply issues and we do not seem to get what we want. The way we are preparing it is a recipe for errors.

    Perfusion Lead, Major Hospital

more than

2M

Cardiac Cases Annually

up to

1.2M

Life Altering Complications

up to

70k

Deaths Annually

up to

55%

Preventable Deaths

up to

20%

From Tamponade*

up to

20%

from poor myocardial protection*

*PerDeCT detects tamponade early and STHpol offers superior myocardial protection

Protecting The Heart

High potassium cardioplegia (the current standard) is suboptimal. Better cardioplegia enables more complex operations on sicker patients.

Predicting Tamponade

PerDeCT™ is the only device for the diagnosis of cardiac tamponade and addresses the unmet need for more accurate diagnosis.

Output Monitoring

Fallouh Health continues to develop a portfolio of life-saving products and medical devices. Get in touch to see how we can partner with you.

To empower clinicians with state of the art solutions they need to improve outcomes for cardiothoracic surgery patients. Our technologies are set apart from the rest because they were born out our first-hand experience as a team at the heart of delivering care for patients undergoing cardiothoracic surgery. We strive to deliver superior care and enhance patient well-being.

By leveraging cutting-edge innovations, we aim to transform the way cardiothoracic surgeries are performed and improve the lives of millions of patients worldwide. Our technologies provide advancements that improve surgical outcomes, enhance patient monitoring, and reduce post-operative complications.

Founded by a practicing cardiothoracic surgeon, our drive has been to address the daily challenges that clinicians experience and simply NEED to find a radical solution for. That’s why our colleagues globally identify with our problems and are eager to use our solutions in order to improve the outcome of our patients.

Our technologies are, by definition, in an uncontested market because they are being developed to address pressing unmet need in cardiothoracic surgery globally. With an estimated 2 million patients undergoing cardiac surgery annually, the opportunity to save lives and costs is huge. Our technologies are simple solutions for complex problems which de-risk our technologies further.

To accelerate the development and commercialisation of our innovative technologies, we are seeking strategic partnerships, investment, and collaboration opportunities. By joining forces with like-minded organisations and individuals, we can unlock new opportunities for growth, expand our reach, and bring our solutions to market faster.

Meet Our Team

Hazem 1

Dr Hazem Fallouh FRCS

CEO

Cardiothoracic surgeon, inventor and founder.
Josh 1

Joshua Purchase MSc

PerDeCT Project Lead

MRes Cardiovascular Sciences and Imaging. Researcher with Medical Devices experience.
Screenshot

Anna Wilson

Project Manager

Medical Scientist with project management and digital leadership experience in big pharma.
Simon 1-2

Simon Manning

Finance Director

Chartered accountant with over 15 years experience in pharma.
Screenshot

Adib Fallouh

Chief Scientific Officer

Over 15 years in the pharmaceutical industry with comprehensive import-export experience.

Partners & Advisors

Prof Tom 1

Prof. Tom Clutton-Brock MBE

PerDeCT Project Partner (Innovate UK)

Professor of Anaesthesia and Intensive Care Medicine at NIHR, MD-TEC & UHB
Alex 1

Prof. Alex Rothman

PerDeCT Project Partner (Innovate UK)

Professor of Cardiology at The University of Sheffield and Honorary Consultant Cardiologist at Sheffield Teaching Hospitals NHS Foundation Trust

Recent News from Fallouh Healthcare

Fallouh Healthcare wins £500k grant from InnovateUK

Fallouh Healthcare, formed by Birmingham cardiothoracic surgeon Hazem Fallouh, has received a £500,000 (€582,000) grant from Innovate UK to develop the new device for early diagnosis of the life-threatening condition. We are now ready to commercialise the technology.

Fallouh Health Techno-College Innovation Award

The European Association of Cardiothoracic Surgeons (EACTS) is the largest professional organisation for cardiothoracic surgeons and the Techno-college Innovation award is one of the most prestigious innovation awards in cardiothoracic surgery.

Proud joiners of Birmingham Research Park

Located at University of Birmingham Enterprise’s medtech incubator, we have access to world-class medical research, proof-of-concept, or prototyping facilities. This is a space where Fallouh Health can continue to innovate, and fulfil its growth potential the medical community.

Get in touch to learn more.

Call us today at +44 7557943226

Send Us A Message

For investors or research partner enquiries, please mention this in the email subject.